2. Search Result
Search Result
Results for "

murine lung cancer

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Peptides

9

Inhibitory Antibodies

2

Natural
Products

3

Oligonucleotides

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146245
    ODN 1826
    5+ Cited Publications

    CpG 1826

    		 Toll-like Receptor (TLR) Apoptosis NO Synthase Cardiovascular Disease Inflammation/Immunology Cancer
    ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .
    ODN 1826
  • HY-146245C
    ODN 1826 sodium
    5+ Cited Publications

    CpG 1826 sodium

    		 Toll-like Receptor (TLR) Apoptosis NO Synthase Cardiovascular Disease Inflammation/Immunology Cancer
    ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .
    ODN 1826 sodium
  • HY-P9964
    Necitumumab

    11F8; IMC-11F8; LY3012211

    		 EGFR Cancer
    Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
    Necitumumab
  • HY-B1114
    Gliquidone
    2 Publications Verification

    AR-DF 26

    		 Potassium Channel ERK STAT NF-κB COX Interleukin Related Reactive Oxygen Species (ROS) Metabolic Disease
    Gliquidone can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone also exhibits good anticancer activity in lung carcinoma cells. Gliquidone has antioxidant property. Gliquidone can be studied in research for type 2 diabetes and cancers .
    Gliquidone
  • HY-P99379
    Nidanilimab (Nadunolimab)

    CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)

    		 Interleukin Related Cancer
    Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
    Nidanilimab (Nadunolimab)
  • HY-P5098
    E(c(RGDfK))2

    		Integrin Neurological Disease Cancer
    E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .
    E(c(RGDfK))2
  • HY-N0600
    Ginsenoside F3

    		Interleukin Related IFNAR NF-κB Inflammation/Immunology
    Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer .
    Ginsenoside F3
  • HY-12929
    NSC756093

    SU093

    		 Pim Apoptosis Cancer
    NSC756093 (SU093) is a GBP1:PIM1 interaction inhibitor. NSC756093 binds to GBP1-PIM1 with a Kd of 38 nM. NSC756093 suppresses proliferation, reduces migration, induces G1 phase cell-cycle arrest, and increases apoptotic cell death in ovarian cancer cells. NSC756093 reduces cellular proteasomal activity, induces accumulation of ubiquitinated proteins, and restrains tumor progression and lung metastasis in murine ovarian cancer xenograft models. NSC756093 increases sensitivity of prostate cancer cells to Docetaxel (HY-B0011) and sensitizes GBP1-overexpressing ovarian cancer cells to Paclitaxel (HY-B0015). NSC756093 can be used for the research of prostate cancer and ovarian cancer .
    NSC756093
  • HY-120275
    CYD-2-11

    		Bcl-2 Family Apoptosis Cancer
    CYD-2-11 is a selective Bax agonist with a Ki value of 34.1 nM. CYD-2-11 induces cell apoptosis and shows antiproliferative activity to breast cancer MDA-MB-231 and MCF-7 cell lines with IC50 values of 3.22 and 3.81 μM, respectively. CYD-2-11 suppresses tumor growth in MDA-MB-231 tumor models. CYD-2-11 can be used for the research of breast and lung cancer .
    CYD-2-11
  • HY-P991608
    CTM01

    7F11C7

    		 Mucin Cancer
    CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
    CTM01
  • HY-139090
    3-Oxobetulin acetate

    28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin

    		 Bacterial HIV Drug Derivative Cancer
    3-Oxobetulin acetate (28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin) is a derivative of betulin (HY-N0083), a cholesterol biosynthesis inhibitor. 3-Oxobetulin acetate inhibits the growth of P388 murine lymphocytic leukemia cells (EC50=0.12 μg/mL) and human MCF-7 breast cancer, SF-268 CNS cancer, H460 lung cancer, and KM20L2 colon cancer cells (GI50s=8, 10.6, 5.2, and 12.7 μg/mL), but not BxPC-3 pancreatic cancer cells or DU145 prostate cancer cells (GI50s=>10 μg/mL for both). 3-Oxobetulin acetate inhibits the replication of X4-tropic recombinant HIV (NL4.3-Ren) in MT-2 lymphoblastoid cells (IC50=13.4 μM). 3-Oxobetulin acetate is also effective against Listeria donovani amastigotes.
    3-Oxobetulin acetate
  • HY-B1114R
    Gliquidone (Standard)

    AR-DF 26 (Standard)

    		 Potassium Channel Reference Standards ERK STAT NF-κB COX Interleukin Related Metabolic Disease
    Gliquidone (Standard) is the analytical standard of Gliquidone. This product is intended for research and analytical applications. Gliquidone can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone also exhibits good anticancer activity in lung carcinoma cells. Gliquidone has antioxidant property. Gliquidone can be studied in research for type 2 diabetes and cancers .
    Gliquidone (Standard)
  • HY-169480
    Lipid C2

    		Liposome Infection Cancer
    Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse T cell exhaustion, as well as increase the percentage of CD3 +CD8 + central and CD3 +CD8 + effector memory T cells and decrease the percentage of CD3 + T cells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .
    Lipid C2
  • HY-N9382
    Gnidimacrin

    		PKC Cancer
    Gnidimacrin is a protein kinase C (PKC) activator. Gnidimacrin inhibits cell growth of human leukemias, stomach cancers and non-small cell lung cancers in vitro, and shows activity against murine leukemias and solid tumors in vivo. Gnidimacrin can be used for leukemias, stomach cancers and non-small cell lung cancers research .
    Gnidimacrin
  • HY-P991600
    Anti-IL-6 Antibody (Chugai SK2)

    		Interleukin Related Inflammation/Immunology Cancer
    Anti-IL-6 Antibody (Chugai SK2) is a murine monoclonal antibody, targeting IL-6. Anti-IL-6 Antibody (Chugai SK2) can be used for inflammatory diseases and cancers research, such as rheumatoid arthritis (RA), crohn's disease (CD) and pancreatic, lung and colon cancer .
    Anti-IL-6 Antibody (Chugai SK2)
  • HY-164441
    Anticancer agent 252

    		Drug Derivative Cancer
    Anticancer agent 252 (compound 1) is a benzamide compound with selective anti-cancer activity against small cell lung cancer (SCLC) cells. Anticancer agent 252 inhibits murine SCLC (mSCLC) cell lines with an average EC50 of 3.21 μM. Anticancer agent 252 also inhibits human SCLC cell lines, H889, H2107, and H128 .
    Anticancer agent 252
  • HY-181663
    PJ27

    		PD-1/PD-L1 JAK Cancer
    PJ27 is a dual PD-1/PD-L1/JAK1 inhibitor, with an IC50 of 414 nM against PD-1/PD-L1, an IC50 of 786 nM against JAK1, a Ka of 294 nM for human PD-1/PD-L1, and a Ka of 473 nM for murine PD-1/PD-L1. PJ27 promotes the infiltration of CD3 +CD8 + and CD3 +CD4 + cells into the tumor microenvironment and exerts a significant immune activation effect. PJ27 inhibits tumor growth in a dose-dependent manner in the LLC lung cancer mouse model. PJ27 is applicable to relevant research on lung cancer .
    PJ27
  • HY-P992095
    Nofetumomab

    		CD20 Cancer
    Nofetumomab is an anti-human monoclonal antibody targeting CD20. Nofetumomab can be used for the research cancer .
    Nofetumomab
  • HY-135146G
    GSK-3484862

    		DNA Methyltransferase Apoptosis Cancer
    GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma .
    GSK-3484862
  • HY-P991744
    Anti-Mouse CXCR4 Antibody (Cx4Mab-1)

    		CXCR Cancer
    Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma .
    Anti-Mouse CXCR4 Antibody (Cx4Mab-1)
  • HY-P991995
    OMTX005

    OMTX705 antibody

    		 ADC Antibody FAP Cancer
    OMTX005 (OMTX705 antibody) is a humanized anti-FAP IgG1 monoclonal antibody that specifically binds to human (EC50: 0.33 nM)/mouse (EC50: 0.14 nM) FAP proteins and FAP-positive cells. OMTX005 exhibits no cytotoxicity when used alone and fails to induce an increase in caspase 3/7 activity in relevant cells. OMTX005 can be used to synthesize the ADC molecule OMTX705 for tumor research .
    OMTX005
  • HY-P992338
    CT-1119

    		Mesothelin Constitutive Androstane Receptor Inflammation/Immunology Cancer
    CT-1119 is an autologous human anti-Mesothelin chimeric antigen receptor macrophage (CAR-M). CT-1119 mediates CAR-dependent, antigen-dependent functional activities. CT-1119 acts as a phagocytosis inducer, tumor cell killer, pro-inflammatory cytokine inducer, and M1 macrophage polarizer. CT-1119 exhibits stronger resistance to M2 repolarization and reduces tumor burden in a mouse lung cancer xenograft model. CT-1119 can be used for the research of mesothelin-expressing solid tumors .
    CT-1119
  • HY-105854A
    Pipoxolan

    		Ras MEK ERK PI3K Akt MMP Keap1-Nrf2 Heme Oxygenase (HO) Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Pipoxolan is an orally active smooth muscle relaxant, anti-inflammatory agent and anticancer agent. Pipoxolan modulates PI3K/AKT signaling pathways, and reduces the levels of Ras/MEK/p-ERK, MMP-2 and MMP-9. Pipoxolan inhibits pro-inflammatory transcription factor pathways, activates Nrf2/HO-1, and suppresses the production of pro-inflammatory mediators. Pipoxolan induces ROS generation, endogenous mitochondrial Apoptosis, and G0/G1 cell cycle arrest. Pipoxolan reduces cerebral infarction size and inhibits intimal hyperplasia. Pipoxolan can be used in research related to cerebral ischemia, intimal hyperplasia, oral squamous cell carcinoma, leukemia and lung cancer .
    Pipoxolan

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: